CSIRO has formed a long-term research alliance agreement with Australian biotechnology company, Circadian Technologies, to develop new potential treatments for cancer.
Under the agreement, CSIRO will work with Circadian on a class of proteins developed by the company, Vascular Endothelial Growth Factors (VEGFs), which play a critical role in regulating tumour blood supply.
Circadian's VEGF technology is based on antibodies blocking VEGF-C, VEGF-D and VEGF receptor R3 proteins to inhibit the growth and spread of cancerous cells or tumours.
Circadian will provide funding and access to its technology and lead drug candidates (molecules), while CSIRO will provide access to its biological production infrastructure, process development capability and research expertise.
The announcement was made at the opening of a new Recombinant Protein Production Facility in Melbourne that is housed in Monash University and CSIRO.
Add a comment